Searchable abstracts of presentations at key conferences in endocrinology

ea0081ep660 | Pituitary and Neuroendocrinology | ECE2022

Automated data extraction of structured clinical correspondence with SNOMED coding to assess regional epidemiology of common pituitary conditions

Hao Alan Yap Shao , Graveling Alex , Abraham Prakash , Philip Sam

Introduction: Pituitary disorders are associated with increased mortality and morbidity. Data on the prevalence of pituitary disorders is scarce. Formal routine coding of diagnoses in outpatient endocrine practice lags behind medical coding of inpatients. Standardised coding could improve our understanding of disease burden and highlight areas of increasing need within our services.Objective: Automatically extract and assign SNOMED codes for endocrine di...

ea0059p140 | Neuroendocrinology and pituitary | SFEBES2018

Metoclopramide Test: Time for a revival in patients without classic symptoms and mild hyperprolactinaemia?

Bhatt Dhruti , Graveling Alex , Philip Sam , Abraham Prakash

Background: Generally Endocrinologists strive to diagnose conditions biochemically prior to radiological investigation. Pituitary incidentalomas are observed in 10% of pituitary MRIs and together with stress induced hyperprolactinaemia, 10–20% of patients receive dopamine agonists (DAs) without a definite diagnosis. Menstrual imbalance is a common symptom of hyperprolactinaemia which can have multiple origins (e.g. hypothalamic, pituitary or ovarian). DAs have side effect...

ea0050p286 | Neuroendocrinology and Pituitary | SFEBES2017

Acromegaly complication screening – are we meeting the guidelines?

Sifontes-Dubon Mildred , Bhatt Dhruti , Murray Lynne , Phull Perminder , Graveling Alex , Philip Sam , Abraham Prakash

Aims: Endocrine Society (ES) acromegaly guidelines (2014) addressed complication screening. Uncontrolled acromegaly is associated with elevated cardiovascular mortality due to risk factors including hypertension (HT), diabetes mellitus (DM), obstructive sleep apnoea (OSA), and with an increased risk of colorectal cancer and polyps among other types of neoplasias. We audited our clinical practice with regards to acromegaly complication screening.Methods: ...

ea0050p289 | Neuroendocrinology and Pituitary | SFEBES2017

Treating mild central hypothyroidism in postoperative pituitary patients – impact of Endocrine Society guidelines

Bhatt Dhruti , Sifontes-Dubon Mildred , Graveling Alex , Philip Sam , Abraham Prakash

Aim: Endocrine Society (2016) published guidelines for hormonal replacement in hypopituitarism. Central hypothyroidism (CH) is defined as fT4 below reference range and mild CH is defined as fT4 in the low-normal range with suggestive symptoms in the context of pituitary disease. In patients with panhypopituitarism levothyroxine in doses sufficient to achieve fT4 levels in the upper half of the reference range is recommended. In our centre...

ea0050p286 | Neuroendocrinology and Pituitary | SFEBES2017

Acromegaly complication screening – are we meeting the guidelines?

Sifontes-Dubon Mildred , Bhatt Dhruti , Murray Lynne , Phull Perminder , Graveling Alex , Philip Sam , Abraham Prakash

Aims: Endocrine Society (ES) acromegaly guidelines (2014) addressed complication screening. Uncontrolled acromegaly is associated with elevated cardiovascular mortality due to risk factors including hypertension (HT), diabetes mellitus (DM), obstructive sleep apnoea (OSA), and with an increased risk of colorectal cancer and polyps among other types of neoplasias. We audited our clinical practice with regards to acromegaly complication screening.Methods: ...

ea0050p289 | Neuroendocrinology and Pituitary | SFEBES2017

Treating mild central hypothyroidism in postoperative pituitary patients – impact of Endocrine Society guidelines

Bhatt Dhruti , Sifontes-Dubon Mildred , Graveling Alex , Philip Sam , Abraham Prakash

Aim: Endocrine Society (2016) published guidelines for hormonal replacement in hypopituitarism. Central hypothyroidism (CH) is defined as fT4 below reference range and mild CH is defined as fT4 in the low-normal range with suggestive symptoms in the context of pituitary disease. In patients with panhypopituitarism levothyroxine in doses sufficient to achieve fT4 levels in the upper half of the reference range is recommended. In our centre...

ea0059p212 | Thyroid | SFEBES2018

Low Dose Radioiodine Therapy for Graves’ disease: comparison of outcomes following administration of different doses across two centres

Sawhney Natasha , Diaz-Ortega Carmen , Philip Sam , Gibb Fraser , Abraham Prakash , Graveling Alex

Introduction: Low dose radioiodine (LDRAI) has been used to treat benign thyroid disease for over 70 years (1). However, controversies remain about the optimal dosage to administer. The Royal College of Physicians guidelines recommend a dosage of 400–600 MBq for uncomplicated Graves’ disease (2); the dose administered varies between centres.Methods: Outcome data at Edinburgh Royal Infirmary were collected retrospectively for patients who receiv...

ea0013p58 | Clinical practice/governance and case reports | SFEBES2007

Extreme pituitary hyperplasia of normal pregnancy presenting as a macroprolactinoma

Acharya Shamasunder , Philip Sam , Danielian Peter , Olson Shona , Bevan John , Abraham Prakash

Case report: A 33-year-old pregnant Nigerian woman presented at 37 wks gestation with a 2-week history of frequent headaches and visual disturbance. She had persistent galactorrhoea following previous pregnancy in 1998, which settled after a short course of bromocriptine. On examination, she had classical bitemporal hemianopia. Her prolactin was raised at 19,220 mU/L (higher than expected in a normal pregnancy), random cortisol 553 nmol/L and thyroid function tests satisfactor...

ea0077p20 | Adrenal and Cardiovascular | SFEBES2021

Adrenal Incidentaloma Pathway - A four-year experience at a teaching hospital

Rajan Roby , Chandy Shekinah Grace K M , Radhakrishnan Parvathy , Paterson Rachel , Aspinall Sebastian , Graveling Alex J , Philip Sam , Abraham Prakash

Background /Methods: Adrenal incidentalomas pose a significant burden to endocrinology services in assessing the clinical significance of these lesions. Following vetting of the incidentaloma referrals, the patients at our centre are initially seen in a nurse-led clinic for biochemical investigations and to ensure completion of radiology assessment using a structured proforma. This step facilitates efficient patient flow and quicker decision making. The clinical outcomes of th...

ea0050p265 | Neuroendocrinology and Pituitary | SFEBES2017

Is 11C-methionine PET co-registered with MRI a game changer for persistent acromegaly?

Bhatt Dhruti , Shyamasunder Asha Hesarghatta , Sifontes-Dubon Mildred , Straiton Jack , Olson Shona , Kamel Mahmoud , Graveling Alex , Philip Sam , Abraham Prakash

Aims: 11C-methionine positron emission tomography co-registered with MRI (met-PET/MRI) is a new imaging technique used for functioning pituitary adenomas. In patients with persistent acromegaly after primary therapy, met-PET/MRI can help identify the site(s) of residual pituitary adenoma when MRI appearances are inconclusive and direct further targeted intervention (Trans-sphenoidal surgery-TSS or radiotherapy).<p class="ab...